Andrew Beelen

Andrew Beelen, MD, serves as Vice President of Clinical Development at Incyclix Bio and is an Industry Advisory Board Member at the Eshelman Institute for Innovation, UNC Eshelman School of Pharmacy. Previous roles include Executive Director and Vice President of Clinical Development at G1 Therapeutics, Senior Director of Clinical Development, and Sr. Medical Director focusing on Oncology Medical Strategy & Science at Quintiles. Andrew also held the position of Director of Clinical Research at Actavis. The educational background includes an MD in Medicine from Upstate Medical University (1993-1997) and further studies at the Geisel School of Medicine at Dartmouth (2000-2002).